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Abstract
Lithium has been the most effective
psychopharmacological drug in the long-term
treatment of patients with recurrent unipolar and
bipolar affective illness. As a result of its widespread
and longtime use in patients with recurrent affective
disorders, psychiatrists have become increasingly
aware of the whole spectrum of lithium’s potential
side effects. One of the side effects associated with its
chronic use is lithium-induced nephropathy. In a
recent cross-sectional study published in BMC
Medicine, Alberto Bocchetta et al. add further
information to this topic, demonstrating that duration
of lithium treatment is associated with impaired
glomerular function in patients with recurrent or
chronic affective disorders. The present paper will
discuss the implications of this and other related
recent research on our management of patients with
recurrent affective disorders. In this context the
importance of shared decision making and close
monitoring of kidney function is highlighted,
including the regular assessment of the glomerular
filtration rate, to provide best possible care to our
patients maintained on lithium treatment.
See related research article here http://www.
biomedcentral.com/1741-7015/11/33
Keywords: lithium, affective disorders, chronic kidney
disease, shared decision making.
Background
For the last few decades lithium has been the most
effective psychopharmacological drug in the long-term
treatment of patients with recurrent unipolar and bipo-
lar affective illness [1]. As a result of its widespread and
longtime use in individual patients with recurrent affec-
tive disorders, psychiatrists have become increasingly
aware of the whole spectrum of lithium’s potential side
effects. One of the side effects associated with its
chronic use is lithium-induced nephropathy (with tubu-
lointerstitial nephritis being the characteristic histo-
pathological finding), which may finally manifest itself as
end-stage renal disease, in need of either dialysis or kid-
ney transplantation [2].
In a recent cross-sectional study published in BMC
Medicine, Alberto Bocchetta et al. add further informa-
tion on this topic, demonstrating that the duration of
lithium treatment is associated with impaired glomerular
function in patients with recurrent or chronic affective
disorders [3]. In their study, for each year of lithium
treatment the estimated glomerular filtration rate (eGFR)
was estimated to decrease by 0.64 mL/minute on average,
in addition to the adverse effects of advancing age. In
patients who had been on lithium for at least 12 months,
chronic kidney disease (defined by an eGFR below 60
mL/minute) was present in about 1 out of 4 patients,
compared to 1 out of 18 in lithium-naïve patients. While
age differences may have contributed to the latter finding
(the lithium treated patients were on average eight years
older than the lithium-naïve patients) these results are in
line with similar data from different research groups dur-
ing previous years [4,5]. Finally, in a recent meta-analysis
lithium treatment was associated with a reduction in
GFR ranging from 0 to 5 mL/minute over a mean obser-
vation time of one year [6]. While 5 mL/minute represent
only 5% of the minimum normal GFR, this may well
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become clinically relevant in patients on long-term
lithium treatment within less than a decade as an eGFR
below 60 mL/minute is already associated with an
increased risk for all-cause mortality and end stage renal
disease [7,8].
Close monitoring of patients on lithium therapy
What are the implications of these findings for the long-
term treatment of patients being treated with lithium in
clinical practice? First of all, kidney function should be
carefully assessed in every patient for whom lithium is
considered a viable treatment option and before treat-
ment is started. In an inpatient setting the measurement
of creatinine clearance is recommended as it usually
accurately reflects glomerular filtration rate and com-
plete 24-hour urine collection is feasible. In an outpati-
ent setting this may be more difficult; therefore,
measuring serum creatinine to calculate the eGFR may
represent a reasonable alternative although it is consid-
ered less precise in the early stages of chronic kidney
disease [9]. The eGFR is either provided directly by the
laboratory or can be calculated with the help of inter-
net-available calculators, for example, from the UK CKD
eGuide on the Renal Association website [10,11]. Com-
pared to the measurement of serum creatinine alone
both parameters are more sensitive to detecting mild
renal insufficiency [4]. If a patient shows values within
the normal range in these assessments and is put on
lithium thereafter, serum creatinine to calculate eGFR
should be assessed at least twice a year, and more fre-
quently if indicated, supplemented by urinanalysis to
assess urine concentration ability and proteinuria. If
eGFR falls below 60 mL/minute/1.73 m2 (generally
referred to as chronic kidney disease) a nephrologist
should be consulted for discussion and more compre-
hensive evaluation. Whether to stop lithium in a patient
with chronic kidney disease should be done in a shared
decision making process, including a discussion of alter-
native treatment options with the patient. Importantly,
stopping lithium may only have beneficial effects for the
kidney as long as the creatinine clearance is > 40 mL/
minute, otherwise the underlying pathology may pro-
gress despite the elimination of the triggering toxic
compound (lithium), with parallel deterioration of kid-
ney function at the same rate as before [12].
Conclusions
In conclusion, while lithium remains one of the most
effective treatment options in the long-term treatment of
patients with recurrent affective disorders, monitoring of
kidney function at least twice a year is mandatory and
should include the assessment of the glomerular filtration
rate either by 24-hour creatinine clearance or eGFR.
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